Atlas Trials

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Clinical trial NCT06235229 · RECRUITING

Trial details

NCT number
NCT06235229
Sponsor
Gracell Biotechnologies (Shanghai) Co., Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2023-12-26
Primary completion
2026-03-02
Enrollment
110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.